Is Rhenium-186 HEDP safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Rhenium-186 HEDP. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Information in this record refers to the use of rhenium-186 HEDP (rhenium-186 etidronate) as a therapeutic agent. No information is available on the therapeutic use of rhenium HEDP during breastfeeding. Because strontium can substitute for calcium in infant bones, the manufacturer and expert opinion recommend discontinuing breastfeeding before a nursing mother receives rhenium HEDP.[1]
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Rhenium 186 emits a beta particle with a mean energy of 0.349 MeV and gamma emission with a 0.137 MeV photo peak. Its physical half-life is 3.7 days.[1]
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Rhenium-186 HEDP” (LM1217). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.